SCHEMBL329804

SCHEMBL329804

c1cc2cc[nH]c2nn1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1765939 0.70 TNF (0.37)
SCHEMBL329830 0.70
SCHEMBL29497464 0.67 ADORA2A (0.57)
SCHEMBL343400 0.67 ADORA2A (0.57)
SCHEMBL17837 0.67
SCHEMBL709685 0.67 AXL (1.00)
SCHEMBL29523425 0.67
SCHEMBL1996526 0.65
Methane SCHEMBL14738986 0.65 AXL (0.95)
Potassium SCHEMBL30760557 0.65 AXL (0.95)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 540 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122070278-A Bifunctional protein degradation agent containing aryl substituted heteroaryl and application thereof 标新生物医药科技(上海)有限公司 2026-05-19 CN claimed
WO-2025101944-A1 COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THAT DEGRADE SWI/SNF-RELATED MATRIX-ASSOCIATED ACTIN-DEPENDENT REGULATOR OF CHROMATIN SUBFAMILY A Plexium, Inc. (US) 2025-05-15 WO claimed
WO-2025082069-A1 COMPOUND BINDING TO CRBN PROTEIN AND DEGRADATION AGENT OF PROTEIN 中国海洋大学 2025-04-24 WO claimed
US-20250099442-A1 COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS PROTHENA BIOSCIENCES INC 2025-03-27 US claimed
EP-4444721-A1 COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS Prothena Biosciences Limited (IE) 2024-10-16 EP claimed
CN-112218631-B Heterocyclic inhibitors of ATR kinase 德州大学系统董事会 2023-12-22 CN claimed
WO-2023107722-A1 COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS PROTHENA BIOSCIENCES LIMITED (IE) 2023-06-15 WO claimed
EP-3765008-B1 HETEROCYCLIC INHIBITORS OF ATR KINASE UNIV TEXAS (US) 2023-06-07 EP claimed
EP-3814357-A1 HETEROCYCLIC AND HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE PTC Therapeutics, Inc. (US) 2021-05-05 EP claimed
US-10894052-B2 Heterocyclic inhibitors of ATR kinase BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2021-01-19 US claimed
CN-112218631-A Heterocyclic inhibitors of ATR kinase 德州大学系统董事会 2021-01-12 CN claimed
US-20190282584-A1 HETEROCYCLIC INHIBITORS OF ATR KINASE ARTIOS PHARMA LIMITED (GB) 2019-09-19 US claimed
US-10093678-B2 Azaspiro derivatives as TRPM8 antagonists RAQUALIA PHARMA INC. (JP) 2018-10-09 US claimed
EP-0534323-B1 Process for the preparation of high chloride tabular grain emulsions (II) EASTMAN KODAK CO (US) 1997-05-14 EP claimed
US-5389509-A Surface treatment of grains with an organonitrogen compound EASTMAN KODAK COMPANY (US) 1995-02-14 US claimed
EP-0534323-A1 Process for the preparation of high chloride tabular grain emulsions (II) EASTMAN KODAK COMPANY (US) 1993-03-31 EP claimed
US-5178997-A A fused N-heterocyclic compound as a grain growth modifier; materials handling EASTMAN KODAK COMPANY (US) 1993-01-12 US claimed
EP-4027995-B1 HPK1 ANTAGONISTS AND USES THEREOF NIMBUS SATURN INC (US) 2026-05-27 EP disclosed
EP-0534323-A1 Process for the preparation of high chloride tabular grain emulsions (II) EASTMAN KODAK COMPANY (US) 1993-03-31 EP disclosed
US-5178997-A A fused N-heterocyclic compound as a grain growth modifier; materials handling EASTMAN KODAK COMPANY (US) 1993-01-12 US disclosed